Discovery Europe 2025

May 2025 | Basel, Switzerland

Pushing traditional boundaries in pharmaceutical science by accelerating the discovery & development of novel therapeutics

Overview Drug Discovery Summit & Discovery Chemistry Neuroscience Drug Development SmartLabs Automation & Robotics

Explore Discovery Europe 2025: Guiding Biopharma From Target Identification To Clinical Candidate

Discovery Europe 2025 features the co-location of 23rd Annual Drug Discovery Summit & Discovery Chemistry Europe and the 6th Annual Neuroscience Drug Development Europe Congresses.

Join and network with over 350 industry discovery biology and chemistry leaders at the renowned Drug Discovery Summit in Basel, where they address critical strategies in target identification, validation and HIT optimisation of small and large molecule drugs. The Drug Design & Medicinal Chemistry focused event also offer insightful innovations in Automation And Synthesis In Organic Chemistry as well as Molecular Drug Design.

Together with Neuroscience Drug Development Europe, attendees especially benefit from an event addressing emerging strategies for the drug development of neuroscience and successful approaches for more targeted, precise, and transformative therapies to neurodegenerative diseases.

23rd Annual Drug Discovery Summit & Discovery Chemistry Europe Congress

Join and network with over 230 industry leaders at the renowned Drug Discovery Summit in Basel, where we will address the latest advancements in target identification, validation and HIT optimisation. The 2-day programme addresses drug discovery in new modalities such as protein degradation, and case studies on the integration of screening approaches in phenotypic and genomics - based discovery, Organ-on-a-chip and 3D modelling. Learn about key focus areas in drug design including AI in drug design: in chemical synthesis, target ID capabilities & lead identification/optimisation.

  • The programme addresses drug discovery in new modalities such as protein degradation, and case studies on the integration of screening approaches in phenotypic and genomics-based discovery, Organ-on-a-chip and 3D modelling.
  • Learn about key focus areas in drug design including AI in drug design: in chemical synthesis, target ID capabilities & lead identification/optimisation.
  • Join our innovation showcase situated alongside the main programme, which aims to inspire growth and create collaboration opportunities for all who attend.

Agenda at a Glance


  • Workshop 1: Organ Modelling
  • Workshop 2: Targeted Protein Degradation
  • Workshop 3: Automation or AI in Medicinal Chemistry and Drug Design

Drug Discovery Summit

  • Day One | Track 1: Identification And Validation Of Novel Targets For Next Generation Therapeutics
  • Day One | Track 2: Animal And Disease Modelling, Organoid And Organ On The Chip Based Discovery
  • Day One | Track 3: Discovery on Target – Screening and Genomic Strategies
  • Day Two | Track 1: Phenotypic & Target Based Discovery Approaches

Drug Design & Medicinal Chemistry Summit

  • Day One | Track 1: Computational Drug Design: AI In Chemical Synthesis, Target ID Capabilities, Lead Identification, Lead Optimisation, Measuring PK/PD & Prediction
  • Day Two | Track 2: Hit Finding Technologies And Advancements
  • Day Two | Track 3, Part 1: Automation And Synthesis In Organic Chemistry
  • Day Two | Track 3, Part 2: Molecular Drug Design And Med Chem: Innovations In Fragment & Structured Based Drug Discovery

6th Annual Neuroscience Drug Development Europe Congress

Addressing emerging strategies for the drug development of neuroscience and successful approaches for more targeted, precise, and transformative therapies to neurodegenerative diseases.

  • Examine the latest advancements and emerging trends in developing neurological treatments, including targeted approaches and novel strategies.
  • Discuss the pioneering innovations in stem cell technologies, with the latest updates on iPS cells for disease modelling and drug discovery. 
  • Establish in-depth knowledge of cutting-edge recent advances in gene therapy for CNS drug discovery and current opportunities for digital biomarkers in neuroscience.

Agenda at a Glance


Day One | Track 1: Therapeutic Strategies, Enabling Technologies & Biomarker Development

Day Two | Track 1: Drug Discovery For Neurodegenerative Disease

4th Annual SmartLabs Automation & Robotics Congress

  • The programme features the innovation and advancement in mobile robot technology and applications, and competitive advantages that can be gained in drug development and pharma manufacturing, automation and logistics.
  • Learn about key focus areas in developments in the automation & digitisation of QA/QC labs, accelerating digital transformation, lab robotics & tools for drug discovery workflows, robotic, process automation and implementing AI/ML in the lab.

Agenda at a Glance


Day One | Track 1: Bridging The Gap Between Automation & Digitalisation through FAIR & Digital Transformation

Day One | Track 2: Smart Manufacturing & Digitisation Optimisation

Day One | Track 3: Mobile Robotics In R&D Laboratories

Day Two | Track 1: Automation with AI/ML & Robotics Tools in Drug Discovery & Development

Day Two | Track 2: Data-Driven Modelling & Data Analytics for Drug Discovery & Development

 

f9d83b55-ff87-4538-a4e2-f67b63da4765-2-5668375logo-Axion-Logo_Tagline_2022

 

Good number of 1-1 meetings with relevant people. Very happy with the networking process and the Oxford Global team are very nice and service minded.


Regional Sales Director
AxionBio

5a563b71-261f-4b78-a13b-5b4890a6b41d-2-5668375logo-Copy-of-Arctoris-blue-logo-1-Transparent

 

Absolutely outstanding conference attracting large pharma and aspiring biotechs. Oxford Global are excellent, the food is outstanding and the preset meetings are informal and impactful

Vice President of Business Development
Arctoris

Novalix Logo

 

The organisation was perfect. Good mix between excellent scientific presentations and network opportunities.


Pharmacology Associate Director
Novalix

novartis-logo

 

This was my first time at the conference and it was a great experience. Very well organized conference and I learned a lot and made valuable connection - Thank you Oxford Global.


Senior Principal Scientist

Novartis

What to Expect

350

leading pharma, biotech & academic delegates

35
hours of presentations, discussions & interactive content
9
hours of networking breaks, including speed networking & refreshments
240
pre-arranged 1-2-1 meetings, facilitating business growth
What to Expect Engaging Thought Leadership
What to Expect Global Technological Showcase
What to Expect Networking Emphasis
What to Expect Innovative Poster Displays

Networking & knowledge-sharing is at the heart of what we do. Alongside the innovative programme, attendees can engage in a variety of event features and make the most of participation in a range of experiences

  • Engaging Thought Leadership

    Over 100 dynamic interactive discussions, roundtables, and presentations curated with insights from top industry leaders and experts
  • Global Technological Showcase

    An international exhibition showcasing cutting-edge technologies and services from leading providers in the scientific field.
  • Networking Emphasis

    Unparalleled networking opportunities, including speed networking sessions, a vibrant drinks reception, and informal gatherings to foster meaningful connections
  • Innovative Poster Displays

    Inspiring poster displays and presentations unveiling the latest breakthroughs from emerging biotech, pharma, and academic institutions

Companies Represented Include

Key Themes for Discovery Europe 2025

The 2025 programme will delve into the intricacies of navigating regulatory barriers in clinical trials, with a specific focus on companion diagnostics (CdX) and the complexities of biomarkers. Discussions will also revolve around the pivotal role of biomarkers in clinical development, exploring advancements in spatial tissue imaging and the integration of AI technologies in biomarker research. With precision medicine also at the forefront, key opinion leaders will examine how these innovations are shaping the landscape of healthcare and the future of personalized treatment approaches within clinical trials. 

Biotech Innovation & Collaboration

Inspiring Tomorrow's Breakthroughs: Unleashing Innovation & Collaboration in Discovery Research & Development

Join engaging presentations featured in our innovation and collaboration track running across day 2 and 3, inspiring growth and creating space for collaboration opportunities for all who attend. The core attendee mix includes early-stage and emerging biotech or (academic) spinoff companies developing their own platforms or technologies with fewer than 30 employees.  

The Innovation & Collaboration track will be comprising of 10-minute presentations and focused panel discussion sessions, encouraging networking, facilitating collaborations & showcasing emerging innovations in biomarkers discovery & development.

Featuring Attendees from Biotech and/or (Academic) Spinoff Companies Interested In:  

  • Seeking collaboration partners with pharma and solution providers 
  • Discovering new investment opportunities with pharma 
  • Learning about the latest industry trends & challenges  
  • Keeping updated with new innovations and technology solutions 
  • Showcasing their company profile to a targeted and engaged audience

2025 Young Scientist Awards (YSA) for Best Poster Presentation

The Discovery Young Scientist Awards include the best poster presentation award and are intended to honour an outstanding individual performance for a scientific work by a PhD student, PostDoc or early career scientist. 

Please submit your poster presentation by no later than 20th December 2024 in the below category: 

  • Emerging Technologies  
  • Biomarkers in Therapeutics  
  • Biomarkers in Diagnostics  
  • Biomarkers in Clinical Trials & Precision Medicine  
  • Omics-Based Biomarker Discovery
  • Student (PhD), PostDoc or early career scientist under 35 years of age. Proof must be provided via an active student ID card or a copy of status
  • Applicants must be the first AND presenting author of the submitted paper and register for the meeting by 20th December 2024
  • ONLY ONE YSA submission per person will be accepted. If authors submit multiple abstracts for consideration for the YSA, only one abstract will be taken into consideration for the YSA

Applicants must follow the procedure as follows: 

  • Register and submit an abstract by 20th December 2024 using the registration link to the left on this page 
  • Once registered you will be provided with the online abstract submission form 
  • Prepare the poster or platform and present it (The poster presenter should be at the poster during all breaks.) 
  • The 3 winners with the highest scores will be announced at the Networking Drinks on the second day of the event 
  • The winners’ 10-minute oral presentations will take place during the networking drinks on day 2 

The platform or poster presentation will be evaluated by senior scientists (consisting of our speaking and steering group committee for the Biomarkers series) on the basis of originality of the approach and quality of the work (e.g. appropriate methodology, interpretation of results, conclusiveness). All participants will receive the scoring and comments after the annual meeting via email.

The 3 winners receiving the highest scores will be announced at the Networking Drinks on the Day 2 and will be given a trophy as well as £1,000 contribution towards travel costs. Oxford Global will also provide winners with PLUS Pass – 12 months access to our content platform providing access to on-demand presentations, exclusive reports and highlights. 

For further information contact help@oxfordglobal.com

Meet Our Expert Speakers

The event brings together a panel of prominent leaders and scientists, sharing new case studies, innovative data, and industry outlooks. Below were some of the featured speakers at Discovery Europe 2024: 22 - 23 May 2024, Basel, Switzerland

Berengere Dumotierd
Associate Director,
NOVARTIS
Davide Gianni
Senior Director,
AstraZeneca
Geoffrey Kerchner
Vice President,
F. Hoffmann-La Roche, Ltd.
Irene Choi
Head of Drug Discovery,
Verge Genomics
Janet Brownlees
Senior Director,
Merck Sharpe and Dohme
Johan Luthman
Executive Vice President of Research & Development,
Lundbeck
nils jakob vest hansen
ceo,
Vipergen ApS
Oliver Hucke
Associate Director,
Boehringer Ingelheim
Sanne Glad
Scientific Director,
Amgen Research Copenhagen
Simona Cotesta
Director,
Novartis
Amelie Joffrin
Investigator,
GSK
Anna Vulpetti
Associate Directir,
Novartis
Anto Pavlovic
Principal Research Associate,
Hoffmann La Roche Ltd
Arianna Sabò
Head of Research & Development,
QUANTRO Therapeutics
Ashutosh Dhingra
Staff scientist,
German Center for Neurodegenerative Diseases (DZNE)-Tübingen
Borislav Dejanovic
Senior Director,
Vigil Neuroscience
Carl Poelking
Associate Director,
Astex
CB Gurumurthy
Professor and Director,
University of Nebraska Medical Center
Daohong Zhou
Professor,
UTHSA
David Bearss
Chief Executive Officer,
Halia Therapeutics
Diana Zindel
Associate Director,
AstraZeneca
Eileen Wegner
Research Associate,
NMI Naturwissenschaftliches und Medizinisches Institut
Emma Davies
Associate Director - Preclinical,
Healx
Eric Goedken
Senior Principal Scientist,
AbbVie
Filip Roudnicky
Senior Principal Scientist,
Roche
Gebhard Thoma
Associate Director,
Novartis
Gergely Toth
Chief Executive Officer & Chief Scientific Officer,
Cantabio Pharmaceuticals
Giovanni Spagnolli
Chief Technology Officer,
Sibylla Biotech
Graham Dempsey
Chief Scientific Officer,
Quiver Bioscience
Gregori Gerebtzoff
Director,
Novartis
Hai Rao
Professor and Chair of Biochemistry,
Southern University of Science and Technology
James Overell
Group Medical Director,
Roche
Jon Lea
Team Leader,
GSK
Jonathan Mason
Senior Research Advisor,
Design for Drug Discovery
Jose Luis Molinuevo
Vice President Head of Experimental Medicine,
H. Lundbeck A/S
Julian Röwe
Senior Scientist,
AbbVie
Kerstin Hofer
Senior Scientist,
Roche
Manuel Stritt
Head Scientific Computing Drug Discovery,
Idorsia Pharmaceuticals
Markus Schade
Principal Scientist,
AstraZeneca
Morten Grunnet
Vice President, Head of Neuroscience and Professor,
H. Lundbeck A/S
Olivier Loiseleur
Senior Team Leader,
Syngenta
Olivier Kitten
Founder and Chief Executive Officer,
Affilogic
Olivier Bugaud
Senior Scientist Assay Development & Technologies,
Galapagos
Paulina Kolasinska-Zwierz
Principal Scientist,
Alchemab
Peter Brandt
Head of Chemistry,
Beactica Therapeutics AB
Richard Lewis
Director,
Novartis
Robin Loving
Chief Scientific Officer,
Salipro Biotech AB
Simon Huet
Senior Scientist,
Affilogic
Takhar Kasumov
Associate Professor,
NEOMED
Ulrike Künzel
Associate Principal Scientist,
Astrazeneca
Urs Langen
Laboratory Head,
Roche
Xinxin Gao
Principal Scientific Manager,
Genentech

Interested in Sponsoring?

Oxford Global’s range of sponsorship opportunities are highly effective in enabling market immersion and visibility, with direct access to clients and potential customers.

Learn more

Latest Resources

Alzheimer's & Brain Awareness Month Spotlight: How Amphista Therapeutics is Tackling Neurological Disorders

To honour Alzheimer's & Brain Awareness Month, this article will acknowledge Amphista Therapeutics' use of targeted protein degradation (TPD) to treat symptoms of neurological disorders.

New Class of Molecular Glues Could Reshape Cancer Drug Discovery

A research group at the University of Dundee discovered new molecular glues, expanding the targeted protein degradation field.

Advancing Cervical Cancer Treatment: FDA Approves Roche's New Self-Collection Option for HPV Testing

The FDA approves a new self-collection test to detect human papillomavirus and identify women at risk for cervical cancer.

New Trailblazer Profluent Launches its AI-enabled OpenCRISPR-1 to Edit the Human Genome

Profluent successfully combined large language models (LLMs) and CRISPR for an open-source AI gene editing project which could reshape CRISPR treatment options.

Beyond Traditional Therapeutics: How Digital Therapeutics Reshape Neurological and Neuropsychiatric Treatments

Two case studies show how digital therapeutics can potentially treat neurological and neuropsychiatric conditions, areas where conventional therapeutics have encountered obstacles.

From Screening to Success: How Molecular 'Super-Glue' SJ3149, Could Advance Cancer Treatments

Researchers at St Jude Children's Research Hospital used high throughput screening (HTS) to identify SJ3149, a molecular glue degrader. This small molecule demonstrated efficacy across a range of cancer types.

Plan Your Visit

Full details regarding accommodation, travel directions, health and safety, and other logistical information for the event will be added here in the coming months.

Register Your Interest

Submit your details and a member of our team will be in touch